go-v.orgdoi

Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial

Changhoon Yoo, Yoon‐Koo Kang · Clinical Investigation · 2015

  • DOI 10.4155/cli.15.26
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2015

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2015

Abstract

Tyrosine kinase inhibitors (TKIs) are the mainstay of the management of advanced gastrointestinal stromal tumors (GISTs). Currently, imatinib, sunitinib and regorafenib are approved treatments for advanced GISTs. However, most standard therapies eventually stop working due to polyclonal evolution of the disease, which results in TKI resistance and overall disease progression. For patients with refractory GISTs after progression on all approved TKIs, resumption of previously effective TKIs may have clinical benefit. However, no randomized trial had been performed to support TKI reuse in patients with advanced GISTs.

Recently, a placebo-controlled randomized Phase III trial (RIGHT) found that imatinib resumption significantly prolonged progression-free survival in patients with TKI-refractory GISTs versus placebo. The details of the RIGHT trial and its clinical implications are reviewed here.

Open the resolved locator · 10.4155/cli.15.26

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 01:30 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.15.26
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.